CARSGEN-B：ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312023.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.CARsgen Therapeutics Holdings Limited科 濟 藥 業 控 股 有 限 公 司(Incorporated in the Cayman Islands with limited liability)(Stock Code:2171)ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31,2023The board(the“Board”)of directors(t

3、he“Directors”)of CARsgen Therapeutics Holdings Limited(the“Company”,“CARsgen Therapeutics”or“CARsgen”)is pleased to announce the audited consolidated results of the Company,its subsidiaries and consolidated affiliated entities(collectively,the“Group”)for the year ended December 31,2023(the“Reporting

4、 Period”),together with the audited comparative figures for the year ended December 31,2022.FINANCIAL HIGHLIGHTSYear ended December 31,20232022RMB000RMB000Net loss(747,794)(892,247)Net loss per share(RMB)(1.34)(1.62)Non-IFRSs MeasuresAdjusted net loss(1)(733,336)(848,252)Adjusted net loss per share(

5、RMB)(1)(1.31)(1.54)As at December 31,20232022RMB000RMB000Cash and bank balances1,849,7522,268,036 Total1,849,7522,268,036 2Our net loss was RMB748 million for the year ended December 31,2023,representing a decrease of RMB144 million from RMB892 million for the year ended December 31,2022.The decreas

6、e was primarily due to(i)the decrease in share-based compensation(“Adjusted Items”),which totaled RMB14 million for the year ended December 31,2023,representing a decrease of RMB30 million from RMB44 million for the year ended December 31,2022;(ii)lower research and development expenses and lower ad